TCA
MTCR

Trifecta Capital Advisors’s Metacrine, Inc. Common Stock MTCR Stock Holding History

Trifecta Capital Advisors’s Portfolio MTCR Stock Details MTCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4,000
Closed -$1.79K – 464
2022
Q4 		$1.79K Buy
+4,000
New +$1.65K ﹤0.01% 323

Other funds holding MTCR

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Trifecta Capital Advisors's MTCR Position: Q1 2023 in Review

Trifecta Capital Advisors sold out of Metacrine, Inc. Common Stock (MTCR) in Q1 2023, closing a stake of 4,000 shares — an estimated $1.79K sold.

Trifecta Capital Advisors first reported a position in MTCR in Q4 2022 and held it in 1 quarter. The position peaked at $1.79K in Q4 2022. 5 funds tracked by Wall St. Rank hold MTCR as of Q1 2023.

  • Trifecta Capital Advisors reported no remaining Metacrine, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Trifecta Capital Advisors sold 4,000 Metacrine, Inc. Common Stock shares in Q1 2023, an estimated $1.79K.
  • Trifecta Capital Advisors first reported a position in Metacrine, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Trifecta Capital Advisors's Metacrine, Inc. Common Stock position peaked at $1.79K in Q4 2022.
  • 5 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q1 2023.

Based on Trifecta Capital Advisors's 13F filing for Q1 2023, filed 9 May 2023.